A phase 1 dose-escalation with expansion study of the antibody-drug conjugate trastuzumab duocarmazine (SYD985) in locally advanced and metastatic solid tumours and HER2-expressing... par Banerji, U, Van Herpen, C, Saura, C, Thistlethwaite, F, Lord, S, Moreno, V, Macpherson, I, Boni, V, Rolfo, C, De Vries, E, Rottey, S, Geenen, J, Eskens, F, Gil-Martin, M, Mommers, E, Koper, N, Aftimos, P

Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high grade serous ovarian and squamous non-small cell lung cancer par Basu, B, Krebs, MG, Sundar, R, Wilson, RH, Spicer, J, Jones, R, Brada, M, Talbot, DC, Steele, N, Garces, AH, Brugger, W, Harrington, EA, Evans, J, Hall, E, Tovey, H, De Oliveira, FM, Carreira, S, Swales, K, Ruddle, R, Raynaud, FI, Purchase, B, Dawes, JC, Parmar, M, Turner, AJ, Tunariu, N, Banerjee, S, De Bono, JS, Banerji, U